Sponsors

Lead Sponsor

Astex Pharmaceuticals, Inc.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Malignant disease appropriate for initiating treatment with carboplatin/paclitaxel, carboplatin/etoposide, topotecan, docetaxel, or erlotinib.
•2. Must be able to read, understand, and sign the IRB approved Informed Consent Form.
•3. At least 18 years old.
•4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
•5. Adequate bone marrow function; normal renal and hepatic function, normal cardiac function.

Exclusion Criteria

•1. Any other active invasive malignancy except non-melanoma skin cancers or cervical carcinoma in situ.
•2. History of significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure and/or myocardial infarction.
•3. Received any anticancer agent(s) within the past 3 weeks, including investigational agents, chemotherapy (6 weeks for nitrosoureas or mitomycin), immunotherapy, biologic or hormonal therapy other than LHRH agonists.
•4. Received prior radiation therapy within the past 4 weeks.
•5. Any serious, uncontrolled active infection that requires systemic treatment or known infection with HIV, HCV or HBV.
•6. Patient requires treatment with immunosuppressive agents other than corticosteroids appropriate for the SOC chemotherapy regimen or those at stable doses for at least 2 weeks.

Related studies

UNKNOWNPhase 1

A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

NCT03560882 · Malignant Disease, Solid Tumor, and more

COMPLETED

Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)

NCT03609814 · Hematologic Malignancies, Nonmalignant Diseases, and more

COMPLETEDPhase 2

A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)

NCT01054456 · Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC

UNKNOWNPhase 1/2

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents

NCT02014506 · Haploidentical Hematopoietic Stem Cell Transplantation, Malignant Disease, and more

COMPLETEDPhase 4

Harmonic ACE®+7 Shears in Laparoscopic Colectomy

NCT02248246 · Benign or Malignant Disease Indicated for Colectomy

Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)

A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents

Harmonic ACE®+7 Shears in Laparoscopic Colectomy

Trial snapshot

Condition

Locations shown

For caregivers